[
  {
    "ts": null,
    "headline": "Incyte Corp. stock underperforms Friday when compared to competitors despite daily gains",
    "summary": "Incyte Corp. stock underperforms Friday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=d88acb45e4a1f9a6398c86139eed6cdb627354ae1059f26127ecf596fa6c17ed",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742577480,
      "headline": "Incyte Corp. stock underperforms Friday when compared to competitors despite daily gains",
      "id": 133416843,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock underperforms Friday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=d88acb45e4a1f9a6398c86139eed6cdb627354ae1059f26127ecf596fa6c17ed"
    }
  },
  {
    "ts": null,
    "headline": "Why Incyte Stock Was Tanking This Week",
    "summary": "A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days.  On Monday, Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe hidradenitis suppurativa (HS), also known as acne inversa.  In each of the trials, the drug met its primary endpoint of a significant (50%-plus) reduction from baseline in abscess and inflammatory nodule count versus a placebo, with no advances in abscess or draining tunnel count.",
    "url": "https://finnhub.io/api/news?id=09d0e2fc2927132c13da8e5df5f398bb7342e2f82425c5ab1c09f10d1c32738f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742572579,
      "headline": "Why Incyte Stock Was Tanking This Week",
      "id": 133327543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days.  On Monday, Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe hidradenitis suppurativa (HS), also known as acne inversa.  In each of the trials, the drug met its primary endpoint of a significant (50%-plus) reduction from baseline in abscess and inflammatory nodule count versus a placebo, with no advances in abscess or draining tunnel count.",
      "url": "https://finnhub.io/api/news?id=09d0e2fc2927132c13da8e5df5f398bb7342e2f82425c5ab1c09f10d1c32738f"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock on Our Watchlist and 2 to Brush Off",
    "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 9.1%. This drop was worse than the S&P 500’s 1.8% loss.",
    "url": "https://finnhub.io/api/news?id=79936ece53cc084a0c92e0abb06b4de40dcb78b801093246472c12ba51c168a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742562068,
      "headline": "1 Healthcare Stock on Our Watchlist and 2 to Brush Off",
      "id": 133327544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 9.1%. This drop was worse than the S&P 500’s 1.8% loss.",
      "url": "https://finnhub.io/api/news?id=79936ece53cc084a0c92e0abb06b4de40dcb78b801093246472c12ba51c168a4"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics",
    "summary": "Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=04a20663c3b5c3252152e08965c8349fa1d9aca071098d6ace3567837727d3e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742546760,
      "headline": "The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics",
      "id": 133325383,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=04a20663c3b5c3252152e08965c8349fa1d9aca071098d6ace3567837727d3e0"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Had a Bad Week. Investors Are Used to It.",
    "summary": "Incyte tumbled more than 8% earlier this week after disappointing Phase 3 study results for povorcitinib, a drug that targets severe hidradenitis suppurativa (HS).  RBC Capital Markets analyst Brian Abrahams warned after the results that sales will almost certainly miss the expected $1 billion mark.  Another analyst, Truist Securities’ Srikripa Devarakonda, noted that HS is a disease that tends to cause variable symptoms in people that respond differently to treatment.",
    "url": "https://finnhub.io/api/news?id=2ad67b0d7b59965461c92eac188016c3bf76ec9cecf4478ace1f44023bd429b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742538600,
      "headline": "Incyte Had a Bad Week. Investors Are Used to It.",
      "id": 133327546,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte tumbled more than 8% earlier this week after disappointing Phase 3 study results for povorcitinib, a drug that targets severe hidradenitis suppurativa (HS).  RBC Capital Markets analyst Brian Abrahams warned after the results that sales will almost certainly miss the expected $1 billion mark.  Another analyst, Truist Securities’ Srikripa Devarakonda, noted that HS is a disease that tends to cause variable symptoms in people that respond differently to treatment.",
      "url": "https://finnhub.io/api/news?id=2ad67b0d7b59965461c92eac188016c3bf76ec9cecf4478ace1f44023bd429b2"
    }
  }
]